by Alliance for Natural Health – USA
We think this is to pave the way for a new blockbuster drug. Action Alert!
In October we told you about a potential new blockbuster drug for Alzheimer’s from drug giant Eli Lilly. Solanezumab is in the third and final phase of FDA drug trials, and if approved, could bring in at least $7.6 billion in sales by 2024 and probably much more. Other drug companies also have “big” Alzheimer’s drugs in the works.
Now the FDA has sent warning letters to five supplement companies targeting the supplement picamilon, …read more
Read more here: Health Impact News
- Rating:
- Views:454 views
- Categories: Health
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr